Actively Recruiting
Led by Rambam Health Care Campus · Updated on 2025-08-01
1084
Participants Needed
14
Research Sites
12 weeks
Total Duration
R
Rambam Health Care Campus
Lead Sponsor
R
Rabin Medical Center
Collaborating Sponsor
Researchers are evaluating the best treatment for bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae bacteria, specifically looking at whether piperacillin-tazobactam is as effective as meropenem. The study focuses on adults with blood infections due to E. coli or Klebsiella species that are resistant to certain antibiotics but susceptible to both study drugs. The trial aims to determine if piperacillin-tazobactam is not worse than meropenem in treating these infections. Participants are randomly assigned to receive either piperacillin/tazobactam at a dose of 4.5 grams four times a day or meropenem at 1 gram three times a day. Both treatments are given to treat the bloodstream infection during the study. The trial includes patients with both community and hospital-acquired infections and excludes those with certain severe conditions or prior infections not fully treated. During the study, participants are monitored for outcomes such as death within 30 days and treatment failure within 7 days after starting treatment. Additional assessments include mortality at 14 and 90 days, microbiological outcomes, infection relapses, hospital readmissions, antibiotic use, resistance development, and adverse events. The study collects detailed data over 90 days to evaluate the safety and impact of these antibiotic treatments.
CONDITIONS
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days from randomization
Participants receive either piperacillin/tazobactam or meropenem as treatment for bloodstream infection caused by cephalosporin-resistant Enterobacteriaceae.
Visits as required during treatment period
Duration - Up to 90 days from randomization
Participants are monitored for treatment outcomes and any adverse events after completion of treatment.
Follow-up visits to assess health status and infection recurrence
Total: 14 locations
1
University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health
Calgary, Alberta, Canada, T2N 4Z6
Actively Recruiting
2
Surrey Memorial Hospital - Fraser Health Authority
Surrey, British Columbia, Canada
Actively Recruiting
3
Eastern Health
St. John's, Newfoundland and Labrador, Canada
Actively Recruiting
4
Kingston General Hospital
Kingston, Ontario, Canada
Actively Recruiting
5
Jewish Genral Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
6
McGill University Health Centre
Montreal, Quebec, Canada
Actively Recruiting
7
Rambam Health Care Campus
Haifa, Israel, Israel, 3435306
Actively Recruiting
8
Soroka Medical Center
Beersheba, Israel
Actively Recruiting
9
Hadassah Medical Center
Jerusalem, Israel
Actively Recruiting
10
Meir Medical Center
Kfar Saba, Israel
Actively Recruiting
11
Sanz Medical Center-Laniado Hospital
Netanya, Israel, 42150
Actively Recruiting
12
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
Actively Recruiting
13
Sheba Medical Center (Tel HaShomer)
Tel Aviv, Israel
Actively Recruiting
14
Sourasky Medical Center
Tel Aviv, Israel
Actively Recruiting
M
Mical Paul, MD
R
Roni Bitterman, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Roni Bitterman, Fidi Koppel, Cristina Mussini...
https://pubmed.ncbi.nlm.nih.gov/33558347